A large number of genes are associated with retinal diseases. RPE65-associated retinal dystrophies are a clinically heterogeneous group of hereditary retinal diseases that have in common a progressive decline in retinal function. Affected persons suffer from retinal degeneration which leads to a loss of visual field and visual acuity up to blindness.
The new therapy marks the beginning of a new era in ophthalmology. „Finally, a new treatment option can be offered to patients suffering from a previously untreatable retinal disease,“ said Professor Siegfried Priglinger, Director of the Eye Clinic.
contact for scientific information:
Professor Dr. Siegfried Priglinger
Director of the Department of Ophthalmology
University Hospital of LMU Munich
Mathildenstrasse 8, 80336 Munich, Germany
Please direct enquiries to
PD Dr. Claudia Priglinger
claudia.priglinger@med.uni-muenchen.de
Maximilian Gerhardt
maximilian.gerhardt@med.uni-muenchen.de
Prof. Dr. Günther Rudolph
guenther.rudolph@med.uni-muenchen.de